Moreover, a study of Ogawa-Momohara et al. indicated that anti-TIF1-γ positivity was correlated with higher tumor staging compared to anti-TIF1-γ negativity in patients with dermatomyositis and cancer [43]. This evidence concerns the gene TRIM33 and dermatomyositis.